PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...
To support patients, BridgeBio will provide Attruby free for life to U.S. clinical trial participants. The company has also ...
We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
Massachusetts Financial Services Co. MA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 23.3% in ...
Scotiabank analyst Greg Harrison maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $310.00.
WorldTrips, based in Carmel, Indiana, a leading provider of global travel medical insurance, is excited to announce the launch of its latest travel medical product, Atlas JapanSecure. This new ...
Zacks.com on MSN18h
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseAlnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by BridgeBio for the distribution of Attrubytm ...
Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback